^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
GENE:

CCNA1 (Cyclin A1)

i
Other names: CCNA1, Cyclin A1, CT146, Cyclin-A1, Testicular Tissue Protein Li 34
Associations
15d
Elucidating the potential carcinogenic molecular mechanisms of parabens in head and neck squamous cell carcinoma through network toxicology and molecular docking. (PubMed, PLoS One)
Parabens may promote HNSCC progression by disrupting cell cycle regulation and immune responses via direct interactions with key hub genes. These findings provide a novel mechanistic basis for the carcinogenic potential of parabens in HNSCC and underscore the need for further experimental and epidemiological validation.
Journal
|
CD8 (cluster of differentiation 8) • CDK4 (Cyclin-dependent kinase 4) • TYMS (Thymidylate Synthetase) • AURKA (Aurora kinase A) • PLK1 (Polo Like Kinase 1) • CHEK1 (Checkpoint kinase 1) • CCNA2 (Cyclin A2) • CDK2 (Cyclin-dependent kinase 2) • CCNB2 (Cyclin B2) • CDK1 (Cyclin-dependent kinase 1) • CCNA1 (Cyclin A1) • CCNB1 (Cyclin B1) • CDC25A (Cell Division Cycle 25A) • GNRP (Ras-Specific Guanine Nucleotide-Releasing Factor 1)
29d
NFIC suppressed the development of Glioma via modulating the balance of SHP2/PI3K and NF-κB/PTEN Signaling. (PubMed, PLoS One)
The overexpression of NFIC has the capacity to inhibit the PI3K/AKT signalling pathway, a process facilitated by the promotion of the expression of OGN and PTEN. This, consequently, results in the inhibition of glioma proliferation and development.
Journal
|
CCND1 (Cyclin D1) • MMP9 (Matrix metallopeptidase 9) • CCNA1 (Cyclin A1) • MMP3 (Matrix metallopeptidase 3) • NFIC (Nuclear Factor I C)
2ms
Mechanisms of Antiproliferative Effects of Nobiletin, Scoparone, and Tangeretin Isolated from Citrus reticulata Peel Dichloromethane Extract in Acute Myeloid Leukemia Cells. (PubMed, Int J Mol Sci)
Moreover, cell treatments attenuated the invasiveness of AML cells through the upregulation of TIMP-2 at the transcriptional level. Therefore, this study supports pharmaceutical interest in citrus waste for cancer management, providing evidence on its antileukemic potential in vitro.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CCND2 (Cyclin D2) • TIMP2 (TIMP Metallopeptidase Inhibitor 2) • CCNA1 (Cyclin A1)
2ms
C21orf2 as a potential regulator of JAK2/STAT3 signaling in prostate cancer cell proliferation and apoptosis: an exploratory study. (PubMed, BMC Cancer)
Our study indicates that C21orf2 is a potential biomarker for the diagnosis and treatment of prostate cancer and highlights its potential as a therapeutic target through the JAK2/STAT3 signaling pathway in prostate cancer.
Journal • IO biomarker
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • CASP3 (Caspase 3) • CCNA1 (Cyclin A1)
2ms
Akt/mTOR pathway-mediated CCNA1 regulation of radiotherapy resistance in nasopharyngeal carcinoma. (PubMed, Cell Oncol (Dordr))
These findings suggest that CCNA1 could serve as a potential predictive biomarker for radiosensitivity in NPC patients, providing new insights for developing personalized comprehensive chemoradiotherapy strategies for NPC patients.
Journal
|
CCNA1 (Cyclin A1)
3ms
Network-based insights into miR-30a-5p-mediated regulation and EGCG targeting in triple-negative breast cancer. (PubMed, Front Bioinform)
The results emphasizes that EGCG has strong binding affinity towards YWHAZ, revealing that miR-30a-EGCG targets TNBC synergistically through cell-cycle-mediated pathways. The findings give rational support for miRNA-guided phytochemical-based TNBC therapeutic development.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor) • PCNA (Proliferating cell nuclear antigen) • RRM2 (Ribonucleotide Reductase Regulatory Subunit M2) • CDC20 (Cell Division Cycle 20) • KIF11 (Kinesin Family Member 11) • ANLN (Anillin Actin Binding Protein) • CCNA1 (Cyclin A1) • MIR30A (MicroRNA 30a) • SKP2 (S-phase kinase-associated protein 2) • YWHAZ (Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Zeta)
|
HER-2 expression
4ms
Farrerol inhibits proliferation and migration of colorectal cancer via the VEGF signaling pathway: evidence from network pharmacology, molecular docking, molecular dynamics simulation, and in vitro experiments. (PubMed, Front Pharmacol)
This study, for the first time, validated the antitumor effect of farrerol against CRC through network pharmacology, molecular docking, molecular dynamics simulations, and in vitro experiments. The findings indicate that the ability of farrerol to inhibit the proliferation and migration of colorectal cancer cells may be associated with the induction of G0/G1 phase cell cycle arrest and the regulation of VEGF signaling pathway activation via binding to VEGFA and KDR.
Preclinical • Journal
|
ER (Estrogen receptor) • CCNE1 (Cyclin E1) • KDR (Kinase insert domain receptor) • CCNA2 (Cyclin A2) • CDK2 (Cyclin-dependent kinase 2) • PTPN1 (Protein Tyrosine Phosphatase Non-Receptor Type 1) • CCNA1 (Cyclin A1) • CDC25B (Cell Division Cycle 25B) • GNRP (Ras-Specific Guanine Nucleotide-Releasing Factor 1) • HSP90AA1 (Heat Shock Protein 90 Alpha Family Class A Member 1Heat Shock Protein 90 Alpha Family Class A Member 1)
5ms
Novel Cyanoacrylamides Incorporating Sulfamethoxazole as Potential Anticancer Agents: DNA Interaction, Apoptotic Induction, and S‑Phase Cell Cycle Arrest in Colon Cancer Cells. (PubMed, ACS Omega)
Compound 9, incorporating the 4-(piperidin-1-yl)-phenyl moiety, was more effective than 5-fluorouracil against the three cell lines...Moreover, the molecular docking supported that compound 9 had good binding affinities toward the active sites of key proteins implicated in carcinogenesis and metastasis. In conclusion, compound 9 is presented as a remarkable molecule for the development of novel anticancer drugs.
Journal
|
BCL2 (B-cell CLL/lymphoma 2) • CDH1 (Cadherin 1) • BIRC5 (Baculoviral IAP repeat containing 5) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • CCNA1 (Cyclin A1)
|
5-fluorouracil
5ms
Reticuline and Coclaurine Exhibit Vitamin D Receptor-Dependent Anticancer and Pro-Apoptotic Activities in the Colorectal Cancer Cell Line HCT116. (PubMed, Curr Issues Mol Biol)
These findings demonstrate that coclaurine and reticuline exert anti-CRC and pro-apoptotic activities via the VDR, suggesting them as natural therapeutic candidates. The use of in vivo CRC models is needed to validate the anticancer activities of coclaurine and reticuline.
Preclinical • Journal • PARP Biomarker • IO biomarker
|
TP53 (Tumor protein P53) • BCL2 (B-cell CLL/lymphoma 2) • CASP3 (Caspase 3) • SNAI1 (Snail Family Transcriptional Repressor 1) • SNAI2 (Snail Family Transcriptional Repressor 2) • CCNA1 (Cyclin A1) • VDR (Vitamin D Receptor)
6ms
Lathyrol inhibits the proliferation of Renca cells by altering expression of TGF-β/Smad pathway components and subsequently affecting the cell cycle. (PubMed, Front Oncol)
Lathyrol can repress the expression of key proteins in the TGF-β/Smad signaling pathway, impede signal transduction, arrest the cell cycle progression of Renca cells, and subsequently inhibit the proliferation of RCC cells. Future studies are needed to further explore the mechanism of lathyrol in RCC treatment.
Journal
|
CCND1 (Cyclin D1) • CCNE1 (Cyclin E1) • CDK4 (Cyclin-dependent kinase 4) • SMAD4 (SMAD family member 4) • CDK6 (Cyclin-dependent kinase 6) • TGFB1 (Transforming Growth Factor Beta 1) • CDK1 (Cyclin-dependent kinase 1) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • CCNA1 (Cyclin A1) • CCNB1 (Cyclin B1) • SMAD2 (SMAD Family Member 2) • SMAD3 (SMAD Family Member 3) • SMAD9 (SMAD Family Member 9)
6ms
Pathways in the brain, heart and lung influenced by SARS-CoV-2 NSP6 and SARS-CoV-2 regulated miRNAs: an in silico study hinting cancer incidence. (PubMed, Cardiooncology)
This study highlights probable hub genes, drugs targeting them, and associated pathways perturbed by SARS-CoV-2 NSP6. Galectin3 (LGALS3) upregulated in both heart and brain after COVID-19 infection is reported to be influencing all the ten hallmarks of cancer. Our bioinformatics and systems study hints probable effect of COVID-19 infection in cancer incidence and warrants in-depth studies for present scenario of long and recurrent COVID-19.
Journal
|
CCND1 (Cyclin D1) • CCNE1 (Cyclin E1) • TGFBR2 (Transforming Growth Factor Beta Receptor 2) • EGF (Epidermal growth factor) • LGALS3 (Galectin 3) • TGFB1 (Transforming Growth Factor Beta 1) • CDKN1B (Cyclin dependent kinase inhibitor 1B) • ATP6AP1 (ATPase H+ Transporting Accessory Protein 1) • CANX (Calnexin) • CCNA1 (Cyclin A1) • CCNB1 (Cyclin B1) • LAMP2 (Lysosomal Associated Membrane Protein 2)
|
Erbitux (cetuximab) • Ibrance (palbociclib) • lapatinib • doxorubicin hydrochloride • irinotecan • methotrexate • Tomudex (raltitrexed) • Davanat (galactomannan)
6ms
ID1 promotes the progression of esophageal cancer via modulating PTEN/YAP/galectin-3 signaling pathway induced proliferation and immune suppression. (PubMed, Sci Rep)
Furthermore, overexpression of ID1 promoted the progression of esophageal cancer, and the expression of ID1 in human cancerous tissues was significantly higher than that in peritumoral tissues. ID1 promotes the progression of esophageal cancer by inducing proliferation and immune suppression through regulation of the PTEN/YAP/Galectin-3 signaling pathway.
Journal
|
PTEN (Phosphatase and tensin homolog) • LGALS3 (Galectin 3) • CCNA1 (Cyclin A1) • ID1 (Inhibitor Of DNA Binding 1, HLH Protein) • NFIC (Nuclear Factor I C)